RxDoctor Payments Data

Justine Lachmann, MD

Cardiovascular Disease · Roslyn, NYNPI 1629135629

Payments from drug & device makers

$1,705in general payments, 2019–2025

Across 75 payments — averaging $22.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$426
  • Novartis$244
  • Medtronic$234
  • Johnson & Johnson$142
  • Pfizer$141
  • E.r. Squibb & Sons, L.L.C.$104
  • plus $414 from 7 others

What the payments were for

  • Food & beverage$1,705100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,705 in reported general payments places this provider in the 50th percentile of 2,302 cardiovascular disease providers in New York.

See all cardiovascular disease providers in New York

Medicare billing

Part B allowed, 2024
$227,339
Medicare patients
2,508
Services billed
5,157

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban108$116,316
JardianceEmpagliflozin73$109,854
FarxigaDapagliflozin Propanediol89$108,897
EntrestoSacubitril/Valsartan83$89,919
XareltoRivaroxaban37$49,190
BrilintaTicagrelor18$16,646
Metoprolol Succinate238$4,105
Torsemide149$2,946
Valsartan101$2,853
Rosuvastatin Calcium193$2,016
Atorvastatin Calcium214$1,733
Telmisartan-HydrochlorothiazidTelmisartan/Hydrochlorothiazid15$1,628
Ranolazine ErRanolazine11$1,547
Carvedilol169$1,281
Colchicine11$1,025

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$141$116,316108 claims
Boehringer IngelheimJardiance$76$109,85473 claims
NovartisEntresto$244$89,91983 claims
Johnson & JohnsonXarelto$142$49,19037 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 2,302 cardiovascular disease providers in New York.

Other cardiovascular disease in Roslyn

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →